跳至主要内容
临床试验/JPRN-UMIN000016283
JPRN-UMIN000016283已完成2 期

Effect of CTLA4-Ig on severe asthma (ECSA) study ; Double blind, placebo controlled, phase IIa trial of CTLA4-Ig (abatacept) on severe asthma - Effect of CTLA4-Ig on severe asthma (ECSA) study

ational Hospital Organization, Sagamihara National Hospital0 个研究点目标入组 30 人开始时间: 2015年2月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Administration of abatacept in the past. Rheumatoid arthritis. Respiratory disorders other than asthma. Current malignancy or past history of (within 5 years) malignancy. Other clinically serious health problems. Active infectious diseases or psoriasis. Those who are pregnant, under-lactation, or desire pregnancy. Administration of live vaccine within past 3 months or during the trial period or those who desire live vaccine within 3 months from the end of the trial. Omalizumab use within past 3 months. History or suspicion of alcohol or drug abuse within past 2 years. Enrollment in other clinical trials within past 3 months. Other conditions that doctors consider not eligible.

研究者

发起方
ational Hospital Organization, Sagamihara National Hospital

相似试验